Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.
2.

Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis.

Ford AC, Delaney BC, Forman D, Moayyedi P.

Am J Gastroenterol. 2004 Sep;99(9):1833-55. Review.

PMID:
15330927
3.

[Cost-benefit analysis of conservative therapy of gastritis and peptic ulcer].

Schütz E, Stolte M.

Leber Magen Darm. 1994 Jul;24(4):147-9. German. No abstract available.

PMID:
7934607
4.

Cost effectiveness in Canada of a multidrug prepackaged regimen (Hp-PAC)+ for Helicobacter pylori eradication.

Agro K, Blackhouse G, Goeree R, Willan AR, Huang JQ, Hunt RH, O'Brien BJ.

Pharmacoeconomics. 2001;19(8):831-43.

PMID:
11596835
5.

[Helicobacter pylori eradication in ulcer patients. Quality of life improves, costs decline].

[No authors listed]

MMW Fortschr Med. 2003 Aug 21;145(33-34):55. German. No abstract available.

PMID:
14526577
6.

Pretreatment antimicrobial susceptibility testing is cost saving in the eradication of Helicobacter pylori.

Romano M, Marmo R, Cuomo A, De Simone T, Mucherino C, Iovene MR, Montella F, Tufano MA, Del Vecchio Blanco C, Nardone G.

Clin Gastroenterol Hepatol. 2003 Jul;1(4):273-8.

PMID:
15017668
7.

Management of Helicobacter pylori in duodenal ulcer: a cost-effectiveness analysis.

García-Altés A, Jovell AJ, Serra-Prat M, Aymerich M.

Aliment Pharmacol Ther. 2000 Dec;14(12):1631-8.

8.

Reappraisal of non-invasive management strategies for uninvestigated dyspepsia: a cost-minimization analysis.

Ladabaum U, Chey WD, Scheiman JM, Fendrick AM.

Aliment Pharmacol Ther. 2002 Aug;16(8):1491-501.

9.
10.

[A cost-effectiveness analysis of strategies for the diagnosis-treatment of Helicobacter pylori-associated peptic ulcer in primary care].

Badia X, Brosa M, Casado A, Segú L, Alvarez A.

Aten Primaria. 1999 Oct 15;24(6):344-51. Spanish.

PMID:
10596225
11.
12.

[Treatment of Helicobacter pylori infection in patients with duodenal ulcer: a cost-benefit study].

Rollán A, Giancaspero R, Acevedo C, Fuster F, Hola K.

Rev Med Chil. 2000 Apr;128(4):367-77. Spanish.

PMID:
10962853
13.

The cost-effectiveness of competing strategies for the prevention of recurrent peptic ulcer hemorrhage.

Ofman J, Wallace J, Badamgarav E, Chiou CF, Henning J, Laine L.

Am J Gastroenterol. 2002 Aug;97(8):1941-50.

PMID:
12190158
14.

Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding.

Leontiadis GI, Sreedharan A, Dorward S, Barton P, Delaney B, Howden CW, Orhewere M, Gisbert J, Sharma VK, Rostom A, Moayyedi P, Forman D.

Health Technol Assess. 2007 Dec;11(51):iii-iv, 1-164. Review.

15.

Pharmacoeconomic comparison of Helicobacter pylori eradication regimens.

Sancar M, Izzettin FV, Apikoglu-Rabus S, Besisik F, Tozun N, Dulger G.

Pharm World Sci. 2006 Aug;28(4):207-14. Epub 2006 Oct 26.

PMID:
17066247
16.
18.

What is the optimal length of proton pump inhibitor-based triple therapies for H. pylori? A cost-effectiveness analysis.

Calvet X, Gené E, López T, Gisbert JP.

Aliment Pharmacol Ther. 2001 Jul;15(7):1067-76.

19.
20.

[Cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: Markov decision analysis].

Wang Q, Jin PH, Lin GW, Xu SR, Chen J.

Zhonghua Liu Xing Bing Xue Za Zhi. 2003 Feb;24(2):135-9. Chinese.

PMID:
12697117
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk